Integrated Investment Consultants’s Genmab GMAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-13,738
Closed -$519K 286
2023
Q1
$519K Sell
13,738
-2,208
-14% -$84.9K 0.16% 98
2022
Q4
$676K Sell
15,946
-2,484
-13% -$102K 0.23% 68
2022
Q3
$592K Sell
18,430
-120
-0.6% -$4.21K 0.24% 66
2022
Q2
$602K Sell
18,550
-1,270
-6% -$41.1K 0.22% 71
2022
Q1
$717K Sell
19,820
-2,670
-12% -$91.6K 0.19% 86
2021
Q4
$889K Sell
22,490
-74
-0.3% -$3.09K 0.24% 75
2021
Q3
$986K Buy
22,564
+414
+2% +$18.6K 0.29% 58
2021
Q2
$905K Buy
22,150
+7,830
+55% +$302K 0.26% 61
2021
Q1
$471K Sell
14,320
-3,080
-18% -$116K 0.16% 117
2020
Q4
$708K Buy
17,400
+1,500
+9% +$56.1K 0.27% 66
2020
Q3
$583K Buy
15,900
+8,450
+113% +$306K 0.27% 70
2020
Q2
$252K Buy
+7,450
New +$203K 0.12% 124

Other funds holding GMAB

Integrated Investment Consultants's GMAB Position: Q2 2023 in Review

Integrated Investment Consultants sold out of Genmab (GMAB) in Q2 2023, closing a stake of 13,738 shares — an estimated $519K sold.

Integrated Investment Consultants first reported a position in GMAB in Q2 2020 and held it in 12 quarters. The position peaked at $986K in Q3 2021. 213 funds tracked by Wall St. Rank hold GMAB as of Q2 2023.

  • Integrated Investment Consultants reported no remaining Genmab position as of Q2 2023 after selling out during the quarter.
  • Integrated Investment Consultants sold 13,738 Genmab shares in Q2 2023, an estimated $519K.
  • Integrated Investment Consultants first reported a position in Genmab in Q2 2020 and held it in 12 quarters.
  • Integrated Investment Consultants's Genmab position peaked at $986K in Q3 2021.
  • 213 funds tracked by Wall St. Rank held Genmab as of Q2 2023.

Based on Integrated Investment Consultants's 13F filing for Q2 2023, filed 18 Jul 2023.